Figure 3 (A–D) shows that, even without clear aberrant marker expression (CD19 covers only a very low frequency CD34+CD38- population), differences in scatter can be used. Since, in this particular AML case, aberrant expression of CD7 was found (Figure 3 E–F), the validity of the scatter approach could be demonstrated (compare Figure 3 E–F with D). The gene discussed is CD34; the disease is acute myeloid leukemia.